文献速递头颈部肿瘤放疗

氯贝胆碱治疗头颈癌患者放射性口干症疗效的系统综述与Meta分析

Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2023-05-18

本文为系统综述与Meta分析,检索Medline/PubMed、Embase、Scopus、LILACS及Web of Science,纳入3项研究共170例患者,评估氯贝胆碱预防头颈癌放疗所致唾液腺功能障碍的效果。Meta分析提示氯贝胆碱与放疗后全刺激唾液(Std. MD 0.66,95% CI 0.28至1.03,P < 0.001)、放疗期间全静息唾液(Std. MD 0.4,95% CI 0.04至0.76,P = 0.03)及放疗后全静息唾液(Std. MD 0.45,95% CI 0.04至0.86,P = 0.03)增加相关。作者认为氯贝胆碱治疗可能对口干症及唾液分泌减少患者有效。

要点

  • 纳入3项研究共170例头颈癌放疗患者,评估氯贝胆碱对唾液腺功能障碍的效果。
  • 氯贝胆碱与放疗后全刺激唾液增加相关(Std. MD 0.66,95% CI 0.28至1.03,P < 0.001)。
  • 氯贝胆碱与放疗期间及放疗后全静息唾液增加相关(P = 0.03)。

核心结论

  • 本研究表明氯贝胆碱治疗可能对头颈癌放疗后口干症及唾液分泌减少患者有效。

研究设计与样本

  • 系统综述与Meta分析,检索Medline/PubMed、Embase、Scopus、LILACS via Portal Regional BVS及Web of Science,遵循Cochrane手册与PRISMA指南报告。
  • 纳入3项研究,共170例患者。

主要发现

  • 氯贝胆碱与放疗后全刺激唾液增加相关(Std. MD 0.66,95% CI 0.28至1.03,P < 0.001)。
  • 氯贝胆碱与放疗期间全静息唾液增加相关(Std. MD 0.4,95% CI 0.04至0.76,P = 0.03)。
  • 氯贝胆碱与放疗后全静息唾液增加相关(Std. MD 0.45,95% CI 0.04至0.86,P = 0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PORPUSE: Salivary glands sustain collateral damage following radiotherapy (RT) to treat cancers of the head and neck, leading to complications, including xerostomia and hyposalivation. This systematic review (SR) with meta-analysis was performed to determine the effectiveness of bethanechol chloride in preventing salivary gland dysfunction in this context. MATERIALS AND METHODS: Medline/Pubmed, Embase, Scopus, LILACS via Portal Regional BVS and Web of Science were searched electronically in accordance with the Cochrane manual and reported PRISMA guidelines. RESULTS: 170 patients from three studies were included. Results from the meta-analysis suggest that bethanechol chloride is associated with increases in: whole stimulating saliva (WSS) after RT (Std. MD 0.66, 95% CI 0.28 to 1.03, P < 0.001); whole resting saliva (WRS) during RT (Std. MD 0.4, 95% CI 0.04 to 0.76, P = 0.03); and WRS after RT (Std. MD 0.45, 95% CI 0.04 to 0.86, P = 0.03). CONCLUSION: The present study suggests that bethanechol chloride therapy may be effective in patients with xerostomia and hyposalivation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Moral Nakamura D, da Graça Pinto H, Baena Elchin C, et al. Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis. Radiother Oncol. 2023. PMID: 37207874. doi:10.1016/j.radonc.2023.109715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。